Atlas Trials

An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

Clinical trial NCT07536815 · AVAILABLE

Trial details

NCT number
NCT07536815
Sponsor
CytoDyn, Inc.
Status
AVAILABLE
Study type
EXPANDED_ACCESS
TNBCTNBC - Triple-Negative Breast CancerTNBC, Triple Negative Breast Cancer

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.